Quick Facts
Plain-English Summary
IGF-LR3 (Insulin-Like Growth Factor-1 Long R3) is a recombinant, engineered analogue of native human IGF-1. It was developed as a research tool — not as a pharmaceutical candidate — to study IGF-1 receptor biology without the confounding effects of rapid binding-protein sequestration that limits native IGF-1 in cell culture and in vivo models. The compound carries two key structural modifications from native IGF-1: a 13-amino acid N-terminal extension and a single amino acid substitution at position 3, replacing arginine with leucine.
These modifications have one dominant consequence: IGF-LR3 binds with dramatically reduced affinity to all six known IGF-binding proteins (IGFBPs). Native IGF-1 has a circulating half-life of approximately 12–15 minutes, largely because IGFBPs sequester it rapidly. IGF-LR3's reduced IGFBP binding extends its functional half-life to approximately 20–30 hours — roughly a 100-fold increase. The compound retains high affinity for the IGF-1 receptor (IGF-1R) and activates the same downstream signalling cascades as native IGF-1.
The primary legitimate use of IGF-LR3 is as a cell culture reagent. It is commercially available from laboratory suppliers (Sigma-Aldrich, Bachem, GroPep) at research grade and is routinely used to study IGF-1 receptor signalling, cell proliferation, satellite cell biology, and cancer biology. In these research contexts, it is a well-characterised, useful tool. Its use in living humans for performance or body composition — the purpose promoted in biohacker communities — is not supported by clinical evidence and raises meaningful safety concerns.
IGF-LR3 is primarily characterised as a laboratory research reagent, not a therapeutic compound. The peer-reviewed human clinical literature specifically for IGF-LR3 is essentially non-existent. Community dosing protocols have no pharmacokinetic validation in humans.
The IGF-1 axis more broadly — through native IGF-1 and its receptor — has been studied in clinical medicine for decades. FDA-approved mecasermin (recombinant native IGF-1) exists for paediatric patients with severe primary IGF-1 deficiency (Laron syndrome). This therapeutic evidence base applies to native IGF-1 in a disease-specific population and cannot be extrapolated to IGF-LR3 use in healthy adults. The substantially longer half-life of IGF-LR3, while scientifically interesting, compounds rather than reduces the safety uncertainty: sustained, unregulated IGF-1R activation carries oncogenic and metabolic risk that has been investigated extensively in cancer biology literature.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rodent muscle satellite cell proliferation | IGF-LR3 and native IGF-1 analogs enhanced satellite cell activation and proliferation following injury. Tomas et al. (1992) demonstrated anabolic effects of Long R3 IGF-I in dexamethasone-treated rats, including preservation of lean mass. Tomas et al. 1992 ↗ | Preclinical |
| Rodent muscle repair model | IGF-1 analogues with reduced IGFBP binding accelerated post-injury regeneration in skeletal muscle crush models vs. native IGF-1. Effect attributed to prolonged receptor engagement. Human translation unestablished. | Preclinical |
| In vitro myoblast differentiation | IGF-LR3 dose-dependently promoted C2C12 myoblast differentiation and protein synthesis at concentrations of 1–100 ng/mL. Widely used in cell biology research as a positive proliferative control. Francis et al. 1994 ↗ | In Vitro |
| Cancer biology — IGF-1R tumour models | Sustained IGF-1R activation (the mechanism of IGF-LR3) consistently promotes tumour cell survival, proliferation, and metastasis across breast, colon, prostate, and lung cancer cell lines. Baserga (1995, 1999) characterised IGF-1R as a "required element" for oncogenic transformation. Baserga 1999 ↗ | Oncology Risk |
| Rodent hypoglycemia studies | IGF-1 and LR3 analogues produce significant insulin-like hypoglycemic effects. Blood glucose suppression dose-dependent; at high doses produced convulsions in rodents. Relevant because IGF-LR3 binds the insulin receptor weakly and activates PI3K/Akt glucose uptake independently. | Safety Signal |
| Receptor downregulation — chronic exposure | Prolonged IGF-1R stimulation in cell culture models produces receptor internalisation and downregulation, blunting subsequent signalling. Whether this occurs in vivo with chronic IGF-LR3 use in humans is unknown. LeRoith & Roberts 2003 ↗ | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Mecasermin (native IGF-1) — Laron Syndrome / severe primary IGF-1 deficiency | Paediatric patients with confirmed IGF-1 deficiency and growth failure. FDA-approved indication (Increlex). | — | Approved (IGF-1) |
| IGF-1 in ALS — Phase III trials | Adults with amyotrophic lateral sclerosis. Native rhIGF-1. Mixed results; not approved for ALS. | — | Inconclusive |
| IGF-LR3 — muscle hypertrophy / body composition in healthy adults | — | — | No Data |
| IGF-LR3 — any indication | — | — | No Data |
IGF-LR3 has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
IGF-LR3 activates the PI3K/Akt/GLUT4 glucose uptake pathway through IGF-1R and exerts partial agonist activity at the insulin receptor. This produces an insulin-like hypoglycemic effect — particularly relevant post-injection. Native IGF-1 in clinical use requires glucose monitoring. In healthy adults using IGF-LR3 without medical supervision, symptomatic hypoglycemia (dizziness, diaphoresis, confusion, seizure) is the most acutely documented risk. Dosing around meals and avoiding fasting states does not eliminate this risk.
The IGF-1 receptor is one of the most extensively characterised oncogenic receptors in cancer biology. Baserga established that IGF-1R signalling is required for oncogenic transformation by several oncoproteins. LeRoith and colleagues demonstrated elevated circulating IGF-1 correlates with increased risk of breast, prostate, and colorectal cancer in epidemiological data. IGF-LR3, which produces sustained, unregulated IGF-1R activation at supra-physiological levels, theoretically poses a tumour promotion risk in individuals with pre-existing or occult malignancy — a population that cannot be identified without screening.
- Chronic IGF-1R stimulation drives receptor internalisation and reduced surface expression
- May blunt endogenous IGF-1 signalling during and after cycles
- Duration and reversibility of downregulation in humans unknown
- Potential interaction with endogenous growth hormone axis not characterised
- No pharmacovigilance database exists for IGF-LR3 in humans
- Any personal or family history of cancer
- Active or suspected malignancy — any type
- Diabetes or impaired glucose regulation
- Pregnancy or breastfeeding
- Children and adolescents (open growth plates)
- Use of insulin or other hypoglycemic agents
- Unmonitored use without blood glucose access
IGF-LR3 is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of IGF-LR3 for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The thing that gets lost in the bodybuilding discourse is that IGF-LR3 was designed specifically as a cell culture tool, not a therapeutic. The IGFBP-resistance modification is genuinely elegant biology — it gives you clean receptor-level data without the confound of binding protein sequestration. That is its value. The leap from "useful in cell culture" to "inject into your thigh after a workout" skips over about thirty steps of translational pharmacology that no one has done.
Exactly. And the half-life extension is the part people celebrate as a feature but it's actually the piece that should give you pause from a safety standpoint. Native IGF-1 having a 15-minute half-life is not an accident — it's part of a tightly regulated feedback loop. Bypassing that regulation for 20+ hours, at concentrations that haven't been established as safe in humans, is a meaningful unknown.
The hypoglycemia risk is real and underdiscussed in this community. I've seen posts where people describe "crashing hard" post-injection and attributing it to "too many carbs" or "insulin sensitivity." That's blood glucose dropping because you've activated the same PI3K/GLUT4 translocation pathway that insulin uses. The Akt arm of IGF-1R signalling is an insulin mimic. People self-dosing without glucose monitoring equipment or a glucagon kit nearby are taking a genuine acute risk that has nothing to do with long-term cancer biology.
The "no cancer risk because it's not HGH" argument I see constantly is just wrong. The epidemiological signal linking elevated IGF-1 to cancer risk is well-established — breast, prostate, colorectal. Baserga's mechanistic work from the 90s showed IGF-1R activation is essentially required for oncogenic transformation downstream of multiple oncoproteins. IGF-LR3 produces sustained, supra-physiological IGF-1R signalling. The question is not whether it could theoretically promote tumour growth in someone with existing disease — it almost certainly could. The question is the probability over the time horizon of use, which nobody has studied.
And you can't screen that risk away. A healthy 28-year-old with no family history and no symptoms could have a subclinical tumour that IGF-1R stimulation accelerates. There is no pre-use test that establishes safety. That asymmetry — where the best-case outcome is modest body composition change and the worst-case is accelerated malignancy — is the honest framing that's absent from vendor marketing.
One thing I don't see discussed: receptor downregulation. In cell culture, sustained IGF-1R stimulation reliably produces receptor internalisation — the cell pulls the receptor off the surface to protect itself from over-signalling. If this occurs in vivo with chronic IGF-LR3 use, you're potentially reducing your sensitivity to endogenous IGF-1 during and after a cycle. Whether that's temporary or semi-permanent, and what the washout curve looks like, has not been studied in humans. The biohacker assumption that "more signal = more muscle indefinitely" ignores basic receptor biology.